Proteins



Fomivirsen sodium

Cat. No.: HY-109528

CAS No.: 160369-77-7

Molecular Weight: 7122.09

Sequence: DNA, d(P-thio)(G-C-G-T-T-T-G-C-T-T-C-T-T-G-C-G), eicosasodium salt

Fomivirsen (sodium)

Target: CMV

Pathway: Anti-infection

Storage: -20°C, stored under nitrogen

* In solvent: -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

SOLVENT & SOLUBILITY

In Vitro

H₂O: 100 mg/mL (14.04 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	0.1404 mL	0.7020 mL	1.4041 mL
	5 mM	0.0281 mL	0.1404 mL	0.2808 mL
	10 mM	0.0140 mL	0.0702 mL	0.1404 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS

Solubility: 100 mg/mL (14.04 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description Fomivirsen (ISIS-2922) sodium is an antisense 21 mer phosphorothioate oligonucleotide. Fomivirsen sodium is an antiviral agent that is used cytomegalovirus retinitis (CMV) research, incluiding in AIDs. Fomivirsen sodium binds to and degrades the

mRNAs encoding CMV immediate-early 2 protein, thus inhibiting virus proliferation^{[1][2]}.

In Vitro Antisense oligonucleotide acts a complementary nucleotide to the messenger RNA of the major immediate-early region

proteins of human cytomegalovirus, it disrupts the replication of the virus through an antisense mechanism $^{[1]}$.

Fomivirsen is 21-mer phosphorothioate ASO with CpG motif near its 5' end, with the sequence 5'-GCG TTT GCT CTT CTT GCG-3', resulting in mRNA degradation by RNase H-mediated mechanism^[2].

Fomivirsen inhibits CMV replication in human retinal pigment epithelial (RPE) cells and in human fibroblast cells (MRC-5 cells) in a dose-dependent manner. The mean IC₅₀ are $0.03 \mu M$ for RPE cells and $0.2 \mu M$ for MRC5 cells^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Page 1 of 2 www.MedChemExpress.com

REFERENCES			
[1]. M D de Smet, et al. Fomiv	rirsen- a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul Immunol Inflamm. 1999 Dec;7(3-4):189-98		
2]. Anna Kilanowska, et al. In vivo and in vitro studies of antisense oligonucleotides – a review. (Review Article) RSC Adv., 2020, 10, 34501-34516			

 $\label{lem:caution:Product} \textbf{Caution: Product has not been fully validated for medical applications. For research use only.}$

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com